Period Prevalence and Perceived Side Effects of Hormonal Contraceptive Use and the Menstrual Cycle in Elite Athletes

Click name to view affiliation

Daniel Martin
Search for other papers by Daniel Martin in
Current site
Google Scholar
PubMed
Close
,
Craig Sale
Search for other papers by Craig Sale in
Current site
Google Scholar
PubMed
Close
,
Simon B. Cooper
Search for other papers by Simon B. Cooper in
Current site
Google Scholar
PubMed
Close
, and
Kirsty J. Elliott-Sale
Search for other papers by Kirsty J. Elliott-Sale in
Current site
Google Scholar
PubMed
Close
Restricted access

Purpose: To identify the period prevalence of hormonal contraceptive (HC) use and characterize the perceived side effects associated with the menstrual cycle and HC use. Methods: A total of 430 elite female athletes completed a questionnaire to assess the period prevalence of HC use, the reasons for initiation and discontinuation of HCs, and the side effects experienced by HC and non-HC users. Descriptive statistics, between-groups comparisons, and associations between categorical variables were calculated. Results: Of athletes studied, 49.5% were currently using HCs and 69.8% had used HCs at some point. Combined oral contraceptives were most commonly used (68.1%), with 30.0% using progestin-only contraceptives (implant = 13.1%, injection = 3.7%, and intrauterine system = 2.8%). Perceived negative side effects were more common with progestin-only HC use (39.1%) compared with combined-HC use (17.8%; P = .001) and were most prevalent in implant users (53.6%; P = .004). HC users reported perceived positive side effects relating to their ability to predict and/or manipulate the timing, frequency, and amount of menstrual bleeding. Non-HC users had a menstrual cycle length of 29 (5) d and 77.4% reported negative side effects during their menstrual cycle, primarily during days 1–2 of menstruation (81.6%). Conclusions: Approximately half of elite athletes used HCs, and progestin-only contraceptive users reported greater incidences of negative side effects, especially with the implant. Because of the high interindividual variability in reported side effects, athletes and practitioners should maintain an open dialogue to pursue the best interests of the athlete.

The authors are with the Sport, Health and Performance Enhancement Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom. Martin is also with the School of Sport and Exercise Science, University of Lincoln, Lincoln, United Kingdom.

Elliott-Sale (kirsty.elliottsale@ntu.ac.uk) is corresponding author.
  • Collapse
  • Expand
  • 1.

    Cable NT, Elliott KJ. The influence of reproductive hormones on muscle strength. Biol Rhythm Res. 2004;35:235244. doi:10.1080/09291010412331335788

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    De Souza MJ, Nattiv A, Joy E, et al. Female Athlete Triad Coalition Consensus Statement on Treatment and Return to Play of the Female Athlete Triad: 1st International Conference held in San Francisco, California, May 2012 and 2nd International Conference held in Indianapolis, Indiana. Br J Sports Med. 2014;48:289. PubMed ID: 24463911 doi:10.1136/bjsports-2013-093218

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Mountjoy M, Sundgot-Borgen J, Burke L, et al. The IOC consensus statement: beyond the Female Athlete Triad--Relative Energy Deficiency in Sport (RED-S). Br J Sports Med. 2014;48:491497. PubMed ID: 24620037 doi:10.1136/bjsports-2014-093502

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Stricker R, Eberhart R, Chevailler MC, et al. Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer. Clin Chem Lab Med. 2006;44:883887. PubMed ID: 16776638 doi:10.1515/CCLM.2006.160

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Brown J, Brown S. Exercise for dysmenorrhoea. Cochrane Database Syst Rev. 2010;(2):CD004142. PubMed ID: 20166071 doi:10.1002/14651858.CD004142.pub2

  • 6.

    Ju H, Jones M, Mishra G. The prevalence and risk factors of dysmenorrhea. Epidemiol Rev. 2014;36:104113. PubMed ID: 24284871 doi:10.1093/epirev/mxt009

  • 7.

    Chantler I, Mitchell D, Fuller A. Diclofenac potassium attenuates dysmenorrhea and restores exercise performance in women with primary dysmenorrhea. J Pain. 2009;10:191200. PubMed ID: 19038583 doi:10.1016/j.jpain.2008.08.006

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Bruinvels G, Burden R, Brown N, Richards T, Pedlar C. The prevalence and impact of heavy menstrual bleeding (menorrhagia) in elite and non-elite athletes. PLoS ONE. 2016;11:0149881. PubMed ID: 26901873 doi:10.1371/journal.pone.0149881

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev. 2009;(2):CD002120. PubMed ID: 19370576 doi:10.1002/14651858.CD002120.pub2

    • Search Google Scholar
    • Export Citation
  • 10.

    Imai A, Matsunami K, Takagi H, Ichigo S. Levonorgestrel-releasing intrauterine device used for dysmenorrhea: five-year literature review. Clin Exp Obstet Gynecol. 2014;41:495498. PubMed ID: 25864246

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Elliott-Sale KJ, Smith S, Bacon J, et al. Examining the role of oral contraceptive users as an experimental and/or control group in athletic performance studies. Contraception. 2013;88:408412. PubMed ID: 23312929 doi:10.1016/j.contraception.2012.11.023

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med. 1990;323:13751381. PubMed ID: 2146499 doi:10.1056/NEJM199011153232003

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Van Den Heuvel MW, Van Bragt AJM, Alnabawy AKM, Kaptein MCJ. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72:168174. PubMed ID: 16102549 doi:10.1016/j.contraception.2005.03.005

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Cea-Soriano L, García Rodríguez LA, Machlitt A, Wallander MA. Use of prescription contraceptive methods in the UK general population: a primary care study. BJOG. 2014;121:5361. doi:10.1111/1471-0528.12465

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Torstveit MK, Sundgot-Borgen J. Participation in leanness sports but not training volume is associated with menstrual dysfunction: a national survey of 1276 elite athletes and controls. Br J Sports Med. 2005;39:141147. PubMed ID: 15728691 doi:10.1136/bjsm.2003.011338

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Brynhildsen J, Lennartsson H, Klemetz M, et al. Oral contraceptive use among female elite athletes and age-matched controls and its relation to low back pain. Acta Obstet Gynecol Scand. 1997;76:873878. PubMed ID: 9351415 doi:10.3109/00016349709024368

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Thein-Nissenbaum JM, Carr KE, Hetzel S, Dennison E. Disordered eating, menstrual irregularity, and musculoskeletal injury in high school athletes. Sports Health. 2014;6:313320. PubMed ID: 24982703 doi:10.1177/1941738113498852

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Thyssen HH, Clevin L, Olesen S, Dennison E. Urinary incontinence in elite female athletes and dancers. Int Urogynecol J Pelvic Floor Dysfunct. 2002;13:1517. PubMed ID: 11999199 doi:10.1007/s001920200003

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Wright KB. Researching internet-based populations: advantages and disadvantages of online survey research, online questionnaire authoring software packages, and web survey services. J Comput Mediat Commun. 2006;10(3). doi:10.1111/j.1083-6101.2005.tb00259.x

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Quinn GP, Keogh MJ. Experimental Design and Data Analysis for Biologists. New York, NY: Cambridge University Press; 2002.

  • 21.

    Daniels K, Daugherty J, Jones J. Current contraceptive status among women aged 15-44: United States, 2011-2013. NCHS Data Brief. 2014;(173):18. PubMed ID: 25500343

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Schaumberg MA, Emmerton LM, Jenkins DG, et al. Oral contraceptive use for manipulation of menstruation in young, physically active women. Int J Sports Physiol Perform. 2018;13(1):8287. doi:10.1123/ijspp.2016-0689

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Vitzthum VJ, Ringheim K. Hormonal contraception and physiology: a research-based theory of discontinuation due to side effects. Stud Fam Plann. 2005;36:1332. PubMed ID: 15828522 doi:10.1111/j.1728-4465.2005.00038.x

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Harada T, Momoeda M. Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2016;106:18071814. PubMed ID: 27717552 doi:10.1016/j.fertnstert.2016.08.051

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Hall KS, Trussell J. Types of combined oral contraceptives used by U.S. women. Contraception. 2012;86:659665. PubMed ID: 22770787 doi:10.1016/j.contraception.2012.05.017

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Nault AM, Peipert JF, Zhao Q, Madden T, Secura GM. Validity of perceived weight gain in women using long-acting reversible contraception and depot medroxyprogesterone acetate. Am J Obstet Gynecol. 2013;208:48.e148.e8. doi:10.1016/j.ajog.2012.10.876

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27.

    Daley AJ. Exercise and primary dysmenorrhoea: a comprehensive and critical review of the literature. Sports Med. 2008;38:659670. PubMed ID: 18620466 doi:10.2165/00007256-200838080-00004

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    McKay J, Niven AG, Lavallee D, White A. Sources of strain among elite UK track athletes. Sport Psychol. 2008;22:143163. doi:10.1123/tsp.22.2.143

All Time Past Year Past 30 Days
Abstract Views 29172 6650 698
Full Text Views 918 235 13
PDF Downloads 906 245 18